TS03 Inc Trust Units TSTIF

RE:RE:RE:RE:Cantel medical

[Drrwong]

Agreed, awareness will be a major focus for the rest of the year.

Listening to all the comments and feedback here and elsewhere, there is no debate that Getinge dropped the ball big time in raising awareness for the VP4 (intentional or not).  Hence, most hospitals, medical lawyers, patients do not even know something like a VP4 exist.

There is now significant acitvity underway for information dissemination and awareness building at multiple levels--clinical, risk management, C-suite, as well as some direct-to-consumer materials to assist healthcare facilities describe why they have chosen a higher level of care in their scope reprocessing.  Just look at last few conferences TSO3 has been/will be going, it includes sterilization (AORN), GI (SGNA) and now infectious disease (AIPC) professionals.  I personally think this catchment strategy is quite sound, and this is a major upside for TSO3 taking control of things with this interim agreement. 

In terms of why Getinge has not done a PR on VP4's duo approval:  my guess is they want to do that only after they have marketing and support material to back that PR up immediately, because just a PR will do little by itself.  Since TSO3 didn't know the timing and LANGUAGE behind the approval ahead of time, it will take a month to create/ready all the marketing material.  Even TSO3's marketing push around the duo approval has not started, but will likely do so soon (within a month of the FDA approval).  My guess is Getinge might do a PR then, once the marketing stuff is ready.  To be fair, many Getinge's sales reps are already aware of the approval, as per their LinkedIn activities.